Trial Information
An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients
Inclusion Criteria:
- Patients receiving Ilaris (canakinumab) at the time of enrollment as part of medical
care
Exclusion Criteria:
- Local regulations in some locations may exclude patients who receive Ilaris for a
non-approved indication
- Other protocol-defined inclusion/exclusion criteria may apply
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
To monitor and further explore the overall safey of canakinumab focusing in serious infections
Outcome Time Frame:
At least 5 years
Principal Investigator
Novartis Pharmaceuticals
Investigator Role:
Study Director
Investigator Affiliation:
Novartis Pharmaceuticals
Authority:
Switzerland: Swissmedic
Study ID:
CACZ885D2401
NCT ID:
NCT01213641
Start Date:
November 2009
Completion Date:
Related Keywords:
- Cryopyrin-associated Periodic Syndromes (CAPS)
- Familial Cold Autoinflam Syn (FCAS)
- Muckle-wells Syn (MWS)
- Neonatal Onset Multisystem Inflam Disease (NOMID)
- Cryopyrin-associated periodic syndromes(CAPS)
- CIAS1 protein
- NLRP3 protein
- human cryopyrin protein
- Familial Cold Autoinflammatory Syndrome(FCAS)
- Muckle-Wells Syndrome(MWS)
- Neonatal Onset Multisystem Inflammatory disease(NOMID)
- NALP3
- canakinumab
- Interleukin-1(IL-1)
- Cryopyrin-Associated Periodic Syndromes
Name | Location |
Rush Presbyterian - St. Lukes Medical Center |
Chicago, Illinois 60612 |
Little Rock Allergy and Asthma Clinic |
Little Rock, Arizona 72205 |
Allergy Center at Brookstone |
Columbus, Georgia 31904 |